FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biotechnology and medicine. What is described is application of a chimeric peptide containing a functional 20-amino acid sequence from the p16INK4a cycline kinase inhibitor and a transport 16-amino acid sequence from the Antp protein for treating cancer selected from a group including colorectal cancer, renal cell carcinoma, lung cancer, breast cancer, bladder cancer, pancreatic cancer, uterine cancer, prostate cancer, stomach cancer and ovarian carcinoma with the transport amino acid sequence attached to an C-end of the specified functional sequence by means of groups X where X represents an amino acid sequence containing 1 - 50 amino acid residues.
EFFECT: invention can be used for creation of the preparation effectively penetrating into target cells and exibiting high cytostatic and cytotoxic action.
4 cl, 19 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC PEPTIDE FOR EPITHELIAL AND MESENCHYMAL MALIGNANT NEOPLASMS TREATMENT | 2008 |
|
RU2369402C1 |
| POLYPEPTIDES FOR TREATING ONCOLOGICAL DISEASES | 2017 |
|
RU2728870C2 |
| CHIMERIC PROTEIN FOR MALIGNANT LYMPHOMA TREATMENT | 2004 |
|
RU2297241C2 |
| CHIMERIC PEPTIDE FOR TREATING BREAST FIBROADENOMA | 2010 |
|
RU2456297C1 |
| ANTIBODY BOUND WITH CARBONIC ANHYDRASE, AND USE THEREOF | 2017 |
|
RU2727682C1 |
| MONOMOLECULAR CHIMERIC T-CELL RECEPTOR TO CANCER ANTIGEN CA125 | 2018 |
|
RU2747095C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT OR PREVENTION | 2013 |
|
RU2631804C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | 2013 |
|
RU2633505C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | 2013 |
|
RU2639522C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | 2013 |
|
RU2632645C2 |
